8-K
filed May 23, 2023, 7:59 PM ET
ticker ALNY
CIK 0001178670
other material
confidence high
sentiment neutral
materiality 0.15
Alnylam shareholders re-elect four Class I directors, approve say-on-pay, ratify auditor
ALNYLAM PHARMACEUTICALS, INC.
- Michael Bonney re-elected with 101.9M for vs 11.8M against; Yvonne Greenstreet 112.4M for vs 1.3M against.
- Phillip Sharp re-elected 101.4M for vs 12.3M against; Elliott Sigal 110.1M for vs 3.6M against.
- Say-on-pay approved: 109.7M for, 4.0M against; 1-year frequency recommended with 113.5M votes.
- PricewaterhouseCoopers ratified as independent auditor for FY2023: 116.1M for, 1.8M against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
ALNYLAM PHARMACEUTICALS, INC. shareholders approved Advisory vote on named executive officer compensation at the 2023-05-18 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-18
Exact text from the filing
The Company’s stockholders approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
ALNYLAM PHARMACEUTICALS, INC. shareholders approved Advisory vote on frequency of future advisory votes on named executive officer compensation at the 2023-05-18 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-05-18
Exact text from the filing
The Company’s stockholders recommended, in a non-binding advisory vote, a frequency of every One Year for future advisory stockholder votes on the compensation of the Company’s named executive officers.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
ALNYLAM PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent auditors at the 2023-05-18 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-18
Exact text from the filing
The Company’s stockholders ratified the appointment by the Company’s Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent auditors for the fiscal year ending December 31, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
ALNYLAM PHARMACEUTICALS, INC. shareholders approved Election of Class I Directors at the 2023-05-18 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-18
Exact text from the filing
The Company’s stockholders re-elected the four persons listed below as Class I directors, each to serve until the Company’s 2026 annual meeting of stockholders or until his or her successor is duly elected and qualified.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.